Physician profile
Luke E Habegger
NPI 1649699893
$1,589.60
in general payments reported to CMS, 2019-2025
17 companies · $88.00 in 2025
The $88.00 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $81.28 · 2021: $562 · 2022: $494 · 2023: $305 · 2024: $59.46 · 2025: $88.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $416 · Education: $36.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $416.06 |
| Education | $36.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $294.99 | 2021-2023 | Ofev |
| Glaxosmithkline, LLC. | $250.39 | 2020-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $206.40 | 2021-2023 | Breztri |
| Mylan Specialty L.P. | $172.67 | 2021-2022 | |
| Grifols USA, LLC | $124.70 | 2021-2023 | Prolastin-C Liquid |
| Csl Behring | $122.31 | 2020-2024 | Kcentra |
| Insmed, INC. | $68.89 | 2021-2025 | Arikayce, Brinsupri |
| Genzyme Corporation | $50.29 | 2020-2021 | |
| Astellas Pharma US INC | $49.09 | 2021 | |
| United Therapeutics Corporation | $47.95 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $41.55 | 2021-2023 | Glassia |
| Becton, Dickinson and Company | $39.46 | 2024 | Hemosphere |
| Pfizer INC. | $35.50 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $30.69 | 2020-2021 | |
| Axsome Therapeutics, INC. | $25.43 | 2025 | Sunosi |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $16.94 | 2021 | |
| Sunovion Pharmaceuticals INC. | $12.35 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luke Habegger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.